Advances in molecular techniques have shown that genetic factors predispose individuals to cardiovascular diseases (CVD). These techniques have made it possible to identify disease‐causing genes, prediction to disease susceptibility and responsiveness to drug interventions. For the purpose of this review, therapeutic intervention (niacin) was conducted in a nonhuman primate model to assess the impact of six coincident single nucleotide polymorphisms (cSNP) identified in prioritised reverse cholesterol transport (RCT) and high‐density lipoprotein (HDL) metabolism genes. Gene expression findings confirmed that these genetic variants may have a direct impact on the RCT pathway and drug intervention (niacin) response.
Part of the book: Advances in Lipoprotein Research